Verastem Stock Forecast, Price & News

+0.06 (+2.22 %)
(As of 09/17/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume5.48 million shs
Average Volume2.59 million shs
Market Capitalization$498.89 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

Verastem logo

About Verastem

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.94 out of 5 stars

Medical Sector

623rd out of 1,351 stocks

Pharmaceutical Preparations Industry

303rd out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Verastem (NASDAQ:VSTM) Frequently Asked Questions

Is Verastem a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Verastem stock.
View analyst ratings for Verastem
or view top-rated stocks.

What stocks does MarketBeat like better than Verastem?

Wall Street analysts have given Verastem a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Verastem wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Verastem's next earnings date?

Verastem is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Verastem

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) announced its quarterly earnings data on Sunday, August, 1st. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.02. Verastem had a negative net margin of 47.93% and a negative trailing twelve-month return on equity of 35.48%.
View Verastem's earnings history

How has Verastem's stock been impacted by COVID-19 (Coronavirus)?

Verastem's stock was trading at $2.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VSTM stock has increased by 13.1% and is now trading at $2.76.
View which stocks have been most impacted by COVID-19

What price target have analysts set for VSTM?

4 brokers have issued 1-year price objectives for Verastem's shares. Their forecasts range from $5.00 to $8.00. On average, they expect Verastem's stock price to reach $6.33 in the next twelve months. This suggests a possible upside of 129.5% from the stock's current price.
View analysts' price targets for Verastem
or view top-rated stocks among Wall Street analysts.

Who are Verastem's key executives?

Verastem's management team includes the following people:
  • Brian M. Stuglik, Chief Executive Officer & Director
  • Dan Paterson, President & Chief Operating Officer
  • Robert E. Gagnon, Chief Financial & Business Officer
  • Jonathan Pachter, Chief Scientific Officer
  • Hagop Youssoufian, Head-Medical Strategy

What is Robert Forrester's approval rating as Verastem's CEO?

11 employees have rated Verastem CEO Robert Forrester on Robert Forrester has an approval rating of 100% among Verastem's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Verastem's key competitors?

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

Who are Verastem's major shareholders?

Verastem's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.74%), BVF Inc. IL (6.24%), Vanguard Group Inc. (4.85%), State Street Corp (3.96%), Geode Capital Management LLC (1.54%) and Acuta Capital Partners LLC (1.12%). Company insiders that own Verastem stock include Ra Capital Management, LP and Timothy J Barberich.
View institutional ownership trends for Verastem

Which major investors are selling Verastem stock?

VSTM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Ikarian Capital LLC, Altium Capital Management LP, Renaissance Technologies LLC, JPMorgan Chase & Co., Acuta Capital Partners LLC, BVF Inc. IL, and Goldman Sachs Group Inc..
View insider buying and selling activity for Verastem
or view top insider-selling stocks.

Which major investors are buying Verastem stock?

VSTM stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Artisan Partners Limited Partnership, Millennium Management LLC, Lord Abbett & CO. LLC, ClariVest Asset Management LLC, Invesco Ltd., Burrage Capital Management LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Verastem
or or view top insider-buying stocks.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $2.76.

How much money does Verastem make?

Verastem has a market capitalization of $498.89 million and generates $88.52 million in revenue each year. The biopharmaceutical company earns $-67,730,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.

How many employees does Verastem have?

Verastem employs 49 workers across the globe.

What is Verastem's official website?

The official website for Verastem is

Where are Verastem's headquarters?

Verastem is headquartered at 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at (781) 292-4200 or via email at [email protected]

This page was last updated on 9/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.